Lund Melanoma Study Group
61 – 70 of 258
- show: 10
- |
- sort: year (new to old)
Close
Embed this list
<iframe src=""
width=""
height=""
allowtransparency="true"
frameborder="0">
</iframe>
- 2023
-
Mark
Phase II LEAP-004 Study of Lenvatinib Plus Pembrolizumab for Melanoma with Confirmed Progression on a Programmed Cell Death Protein-1 or Programmed Death Ligand 1 Inhibitor Given as Monotherapy or in Combination
- Contribution to journal › Article
- 2022
-
Mark
Copy number variants are ovarian cancer risk alleles at known and novel risk loci
- Contribution to journal › Article
-
Mark
Distinct Reproductive Risk Profiles for Intrinsic-Like Breast Cancer Subtypes : Pooled Analysis of Population-Based Studies
- Contribution to journal › Article
-
Mark
Quality of Life in the First Year of Follow-Up in a Randomized Multicenter Trial Assessing the Role of Imaging after Radical Surgery of Stage IIB-C and III Cutaneous Melanoma (TRIM Study)
- Contribution to journal › Article
-
Mark
Neoantigen-reactive CD8+ T cells affect clinical outcome of adoptive cell therapy with tumor-infiltrating lymphocytes in melanoma
- Contribution to journal › Article
-
Mark
Interplay between Caveolin-1 and body and tumor size affects clinical outcomes in breast cancer
- Contribution to journal › Article
-
Mark
Transcriptomic signatures of tumors undergoing T cell attack
- Contribution to journal › Article
-
Mark
Incidence and trends of basal cell carcinoma in Sweden : A population-based registry study
- Contribution to journal › Article
-
Mark
Physical activity, sedentary time and breast cancer risk : a Mendelian randomisation study
- Contribution to journal › Article
-
Mark
Immediate increase in perceived energy after exercise during the course of chemotherapy treatment for breast cancer
- Contribution to journal › Article
